Original articleMethotrexate-induced congenital malformations: With a review of the literature
References (9)
Therapeutic abortions with a folic acid antagonist, 4-amino pteroylglutamic acid, administered by the oral route
Am. J. Obst. & Gynec.
(1952)Congenital malformation due to attempted abortion with aminopterin
Am. J. Obst. & Gynec.
(1962)The control of reproduction in rats with the aid of antimetabolites, and early experiences with antimetabolites as abortifacient agents in man
Acta endocrinol.
(1956)- et al.
Attempted abortion with aminopterin (4-amino-pteroylglutamic acid)
Am. J. Dis. Child.
(1959)
There are more references available in the full text version of this article.
Cited by (248)
Prognostic factors for spontaneous resolution of an ectopic pregnancy
2023, European Journal of Obstetrics and Gynecology and Reproductive BiologyFocus on germ-layer markers: A human stem cell-based model for in vitro teratogenicity testing
2020, Reproductive ToxicologyFetal methotrexate syndrome: A systematic review of case reports
2019, Reproductive ToxicologyCitation Excerpt :Manual search of reference lists did not yield any additional articles. The 23 articles that were included reported on a total of 29 cases of in utero methotrexate exposure [1,7–28]. Methotrexate was used in 45% (13 out of 29 cases) for treatment of a maternal disease (rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, psoriasis or molar pregnancy).
Chemotherapy in pregnancy
2016, Best Practice and Research: Clinical Obstetrics and GynaecologyReproductive Complications
2013, Abeloff's Clinical Oncology: Fifth Edition
Copyright © 1968 Published by Mosby, Inc.